AORT vs the Competition: Which Stock Comes Out on Top?
Here is how Artivion (AORT) stacks up against its peers in size, valuation, growth and margin.
- AORT’s operating margin of 4.3% is modest, lower than most peers – trailing IDXX (31.1%).
- AORT’s revenue growth of 7.4% in the last 12 months is moderate, outpacing IDXX but lagging ATRC, UFPT, MASI, EW.
- AORT gained 70.1% in the past year and trades at a PE of -106.6, outperforming its peers.
As a quick background, Artivion provides medical devices and implantable human tissues worldwide, including BioGlue polymer and E-xtra design engineering systems for treating aortic vascular diseases.
| AORT | ATRC | UFPT | MASI | EW | IDXX | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 1.9 | 1.7 | 1.7 | 7.8 | 47.6 | 50.9 |
| Revenue ($ Bil) | 0.4 | 0.5 | 0.6 | 1.8 | 5.7 | 4.0 |
| PE Ratio | -106.6 | -46.9 | 25.2 | -17.1 | 11.5 | 51.6 |
| LTM Revenue Growth | 7.4% | 16.3% | 41.0% | 8.0% | 9.1% | 6.7% |
| LTM Operating Margin | 4.3% | -6.8% | 16.6% | 6.5% | 27.9% | 31.1% |
| LTM FCF Margin | 1.9% | 1.7% | 12.3% | 7.3% | 10.2% | 19.2% |
| 12M Market Return | 70.1% | 48.9% | -32.6% | 16.9% | 15.8% | 27.9% |
Why does this matter? AORT just went up 38.1% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell AORT Stock to see if Artivion holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through AORT Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| AORT | 7.4% | 9.8% | 12.8% | 5.0% |
| ATRC | 16.3% | 16.5% | 20.8% | 20.4% |
| UFPT | 41.0% | 26.1% | 13.1% | 71.5% |
| MASI | 8.0% | 2.3% | 0.6% | 64.3% |
| EW | 9.1% | 8.6% | 12.2% | -14.7% |
| IDXX | 6.7% | 6.5% | 8.7% | 4.7% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| AORT | 4.3% | 10.0% | -2.4% | 2.0% |
| ATRC | -6.8% | -8.6% | -6.7% | -12.9% |
| UFPT | 16.6% | 16.7% | 15.3% | 12.6% |
| MASI | 6.5% | 1.8% | 8.0% | 10.3% |
| EW | 27.9% | 27.2% | 29.7% | 34.5% |
| IDXX | 31.1% | 29.0% | 30.0% | 26.7% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| AORT | -106.6 | -89.2 | -23.7 | -25.3 |
| ATRC | -46.9 | -32.1 | -54.3 | -43.7 |
| UFPT | 25.2 | 31.8 | 29.2 | 21.3 |
| MASI | -17.1 | -28.9 | 75.9 | 55.3 |
| EW | 11.5 | 10.6 | 33.0 | 30.3 |
| IDXX | 51.6 | 38.4 | 54.6 | 50.2 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.